These videos illustrate a robotic solution to the complex problem of very large prostate glands causing severe lower urinary tract symptoms.
Modern Medicine Feature Articles
In this video, Trinity J. Bivalacqua, MD, PhD, presents the case of a 63-year-old man with history of carcinoma in situ found to have low-grade Ta non-muscle invasive bladder cancer.
"In order to complete our transformation into urologists, we must learn to understand and respect the multifaceted importance of responsibility for our patients, our teachers, and our mentees," writes Nirmish Singla, MD.
Studies provide clear evidence to support MRI fusion biopsy’s use as the gold standard for men at risk for prostate cancer diagnosis following an initial negative biopsy.
Other products discussed in this round-up include a rectal spacer, an imaging agent for prostate cancer, and an app to help health care professionals choose the safest contrast agent when imaging patients with renal impairment.
Agents for bladder cancer, mixed incontinence, and interstitial cystitis/bladder pain syndrome are also included in this overview of pipeline developments.
Limitations of MRI fusion biopsy include its cost, interobserver variability, and low diagnostic accuracy for clinically significant cancer in the anterior prostate.
Evidence shows HIFU can provide cancer control outcomes comparable to those associated with radical prostatectomy or radiation therapy in properly selected patients.
Recommending either whole-gland or focal HIFU cannot be justified when their pros and cons are judged relative to the appropriate comparator.
Based on recent developments with blue light cystoscopy, the use of white light cystoscopy alone is now considered suboptimal as a diagnostic tool.